Our Services

Cannabis

IMP Clinical Supply Services holds the IMC-GDP  license issued by the Israeli Ministry of Health, which is mandatory in to provide services as importation, storage distribution, and destruction for cannabis clinical trials.

Cannabis remains a controlled substance worldwide; therefore, the innovative medicalization process established in Israel requires compliance to strict guidelines issued by the Israeli Medical Cannabis (IMC) unit, Good Agriculture Practice (IMC-GAP), Good Manufacturing Practice (IMC-GMP), Good Distribution Practice (IMC-GDP) and Good Security Practice (IMC-GSP).

Israel is considered a global leader in the research of cannabis for medical purposes. The medicalization process enables the conduct of clinical trials in Israel with cannabis via new usages. IMP’s IMC-GDP permit represents a milestone for our company, enhancing our contribution to the increasing amount of clinical trials conducted with Cannabis, for current and future studies in Israel.

 

Cannabis

IMP Clinical Supply Services holds the IMC-GDP  license issued by the Israeli Ministry of Health, which is mandatory in to provide services as importation, storage distribution, and destruction for cannabis clinical trials.

Cannabis remains a controlled substance worldwide; therefore, the innovative medicalization process established in Israel requires compliance to strict guidelines issued by the Israeli Medical Cannabis (IMC) unit, Good Agriculture Practice (IMC-GAP), Good Manufacturing Practice (IMC-GMP), Good Distribution Practice (IMC-GDP) and Good Security Practice (IMC-GSP).

Israel is considered a global leader in the research of cannabis for medical purposes. The medicalization process enables the conduct of clinical trials in Israel with cannabis via new usages. IMP’s IMC-GDP permit represents a milestone for our company, enhancing our contribution to the increasing amount of clinical trials conducted with Cannabis, for current and future studies in Israel.